In Brief: Wellcome's Flolan

Wellcome's Flolan: Antihypertensive drug epoprostenol is "approvable" at FDA for treatment of severe primary pulmonary hypertension but not for congestive heart failure patients with left ventricular systolic dysfunction as reported in the May 15 issue of "The Pink Sheet" (In Brief). Trials of Flolan for patients with severe end-stage congestive heart failure were halted when interim analyses showed Flolan patients had higher mortality rates than those receiving standard therapies ("The Pink Sheet" June 28, 1993, In Brief)...